Adjuvant chemotherapy vs. observation in stage I clear cell ovarian carcinoma: A systematic review and meta-analysis

A systematic review and meta analysis has been undertaken in order to evaluate the effectiveness of adjuvant therapy following surgery for early ovarian cancer. Trials reported since 1990 have been of a higher quality enabling a meta analysis of adjuvant chemotherapy vs adjuvant radiotherapy and a meta analysis of adjuvant chemotherapy vs observation. There was no significant difference between radiotherapy and chemotherapy, though these comprised studies which demonstrated considerable heterogeneity. Chemotherapy did confer significant benefit over observation in terms of both overall and disease free survival. Except for women in whom adequate surgical staging has revealed well differentiated disease confined to one or both ovaries with intact capsule, platinum chemotherapy should be offered to reduce risk of recurrence.

Download Full-text

The role of FOXC1 in clear cell ovarian carcinoma: Potential prognostic biomarker for aggressive disease?

Gynecologic Oncology ◽

10.1016/j.ygyno.2015.07.083 ◽

2015 ◽

Vol 139 (1) ◽

pp. 204

Author(s):

T.J. Vogel ◽

J. Cohen ◽

B. Han ◽

A.E. Walts ◽

X. Zhang ◽

...

Keyword(s):

Ovarian Carcinoma ◽

Clear Cell ◽

Prognostic Biomarker ◽

Aggressive Disease ◽

Clear Cell Ovarian Carcinoma

Download Full-text

Delay in adjuvant chemotherapy administration for patients with FIGO stage I epithelial ovarian carcinoma is associated with worse survival

Gynecologic Oncology ◽

10.1016/s0090-8258(21)00878-7 ◽

2021 ◽

Vol 162 ◽

pp. S124

Author(s):

Dimitrios Nasioudis ◽

Spyridon Mastroyannis ◽

Emily Ko ◽

Ashley Haggerty ◽

Lori Cory ◽

...

Keyword(s):

Adjuvant Chemotherapy ◽

Ovarian Carcinoma ◽

Figo Stage ◽

Epithelial Ovarian Carcinoma ◽

Stage I ◽

Chemotherapy Administration

Download Full-text

Adjuvant chemotherapy for resected biliary tract cancers: a systematic review and meta-analysis

HPB ◽

10.1016/j.hpb.2017.05.010 ◽

2017 ◽

Vol 19 (9) ◽

pp. 741-748 ◽

Cited By ~ 23

Author(s):

Michele Ghidini ◽

Gianluca Tomasello ◽

Andrea Botticelli ◽

Sandro Barni ◽

Giampietro Zabbialini ◽

...

Keyword(s):

Systematic Review ◽

Adjuvant Chemotherapy ◽

Biliary Tract ◽

Meta Analysis ◽

Biliary Tract Cancers

Download Full-text

Segmentectomy versus lobectomy for stage I non-small cell lung cancer: a systematic review and meta-analysis

Journal of Thoracic Disease ◽

10.21037/jtd.2017.05.79 ◽

2017 ◽

Vol 9 (6) ◽

pp. 1615-1623 ◽

Cited By ~ 23

Author(s):

Benedetta Bedetti ◽

Luca Bertolaccini ◽

Raffaele Rocco ◽

Joachim Schmidt ◽

Piergiorgio Solli ◽

...

Keyword(s):

Lung Cancer ◽

Systematic Review ◽

Small Cell Lung Cancer ◽

Cell Lung Cancer ◽

Meta Analysis ◽

Small Cell ◽

Stage I ◽

Small Cell Lung

Download Full-text

Impact of Lymphadenectomy on the Oncologic Outcome of Patients with Adrenocortical Carcinoma—A Systematic Review and Meta-Analysis

Cancers ◽

10.3390/cancers14020291 ◽

2022 ◽

Vol 14 (2) ◽

pp. 291

Author(s):

Anne Hendricks ◽

Sophie Müller ◽

Martin Fassnacht ◽

Christoph-Thomas Germer ◽

Verena A. Wiegering ◽

...

Keyword(s):

Systematic Review ◽

Adrenocortical Carcinoma ◽

Survival Benefit ◽

Meta Analysis ◽

Postoperative Mortality ◽

Length Of Hospital Stay ◽

Oncologic Outcome ◽

Stage I ◽

Tumor Stages ◽

The Impact

(1) Background: Locoregional lymphadenectomy (LND) in adrenocortical carcinoma (ACC) may impact oncological outcome, but the findings from individual studies are conflicting. The aim of this systematic review and meta-analysis was to determine the oncological value of LND in ACC by summarizing the available literature. (2) Methods: A systematic search on studies published until December 2020 was performed according to the PRISMA statement. The primary outcome was the impact of lymphadenectomy on overall survival (OS). Two separate meta-analyses were performed for studies including patients with localized ACC (stage I–III) and those including all tumor stages (I–IV). Secondary endpoints included postoperative mortality and length of hospital stay (LOS). (3) Results: 11 publications were identified for inclusion. All studies were retrospective studies, published between 2001–2020, and 5 were included in the meta-analysis. Three studies (N = 807 patients) reported the impact of LND on disease-specific survival in patients with stage I–III ACC and revealed a survival benefit of LND (hazard ratio (HR) = 0.42, 95% confidence interval (95% CI): 0.26–0.68). Based on results of studies including patients with ACC stage I–IV (2 studies, N = 3934 patients), LND was not associated with a survival benefit (HR = 1.00, 95% CI: 0.70–1.42). None of the included studies showed an association between LND and postoperative mortality or LOS. (4) Conclusion: Locoregional lymphadenectomy seems to offer an oncologic benefit in patients undergoing curative-intended surgery for localized ACC (stage I–III).

Download Full-text

Impact of BRAF mutations on prognosis and immunotherapy response in microsatellite instability/mismatch repair deficient metastatic colorectal cancer: A systematic review and meta-analysis.

Journal of Clinical Oncology ◽

10.1200/jco.2021.39.15_suppl.3557 ◽

2021 ◽

Vol 39 (15_suppl) ◽

pp. 3557-3557

Author(s):

Robin Park ◽

Laércio Lopes da Silva ◽

Sunggon Lee ◽

Anwaar Saeed

Keyword(s):

Colorectal Cancer ◽

Systematic Review ◽

Braf Mutation ◽

Meta Analysis ◽

Stage Iv ◽

Stage I ◽

Prognostic Impact ◽

Braf Mutations ◽

Mutation Status ◽

The Impact

3557 Background: Mismatch repair deficient/microsatellite instability high (dMMR/MSI-H) colorectal cancer (CRC) defines a molecular subtype with distinct clinicopathologic characteristics including an excellent response to immunotherapy. Although BRAF mutations are established as a negative prognostic marker in CRC, whether they retain their negative prognostic impact in or alter the response to immunotherapy in dMMR/MSI-H CRC remains unknown. Herein, we present a systematic review and meta-analysis of the impact of BRAF mutations on the overall survival (OS) and immune checkpoint inhibitor (ICI) response in dMMR/MSI-H CRC. Methods: Studies published from inception to 26 January 2021 were searched in PubMed, Embase, and major conference proceedings (AACR, ASCO, and ESMO). Eligible studies included the following: 1) observational studies reporting outcomes based on BRAF mutation status in dMMR/MSI-H CRC patients and 2) experimental studies of ICI reporting outcomes based on BRAF mutation status in dMMR/MSI-H CRC patients. A summary hazard ratio (HR) was calculated for OS in BRAF mutated ( BRAFmut) vs. BRAF wild type ( BRAFwt) patients (pts) with the random effects meta-analysis (REM). A summary odds ratio (OR) was calculated for objective response rate (ORR) in BRAFmut vs. BRAFwt pts treated with ICI with the REM. Results: Database search conducted according to PRISMA guidelines found 4221 studies in total. Initial screening identified 30 studies and after full-text review, 9 studies (N = 4158 pts) were included for the meta-analysis of prognosis (analysis A) and 3 studies (N = 178 pts) were included for the meta-analysis of ICI response (analysis B). The outcome measures are summarized in the table below. Analysis A showed that in stage I-IV dMMR/MSI-H CRC pts, BRAFmut was associated with worse OS than BRAFwt (HR 1.57, 1.23-1.99). The heterogeneity was low (I2 = 21%). Subgroup analysis showed no significant difference in the prognostic impact of BRAF mutation status between stage IV only and stage I-IV CRC pts. Analysis B showed no difference in ORR (OR 1.04, 0.48-2.25) between BRAFmut vs. BRAFwt dMMR/MSI-H pts who received ICI. The heterogeneity was low (I2 = 0%). Conclusions: BRAF mutations retain their negative prognostic impact in dMMR/MSI-H stage I-IV and stage IV CRC but are not associated with differential ICI response. Limitations include the following: analysis A was based on retrospective studies; also, the impact of BRAF status on the survival outcome of ICI could not be assessed due to limited number of studies.[Table: see text]

Download Full-text